Shares of Immunogen IMGN gained 10% in pre-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share were up 43.33% over the past year to ($0.17), which missed the estimate of ($0.15).
Revenue of $13,287,000 higher by 54.79% from the same period last year, which missed the estimate of $14,940,000.
Outlook
Immunogen hasn't issued any earnings guidance for the time being.
Immunogen hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: May 01, 2020
Time: 12:00 PM ET
Webcast URL: https://edge.media-server.com/mmc/p/38zm7g3c
Recent Stock Performance
Company's 52-week high was at $7.07
Company's 52-week low was at $1.76
Price action over last quarter: down 30.78%
Company Overview
Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.